# Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes

> **NCT00351923** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 330 (—)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** MeMuRu-OKA (study vaccine)

## Key facts

- **NCT ID:** NCT00351923
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 330 (—)
- **Last updated:** 2008-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351923, "Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00351923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*